Financing drug development via adaptive platform trials
PLOS One · 02.07.2025 · 20 (7) · e0325826
DOI: 10.1371/journal.pone.0325826 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 02.07.2025. Verfasst von Joonhyuk Cho und 12 weiteren Autor:innen. Beteiligte Einrichtung: MIT Laboratory for Financial Engineering, Cambridge, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Drug Development, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We propose a new approach to funding disease-specific drug development via a variation of the adaptive platform trial. This trial is designed to test a portfolio of drug candidates in parallel, with the cost of the trial partially covered by investors who receive payments from a royalty fund of the candidates in exchange for investment. Under realistic assumptions for cost, revenue, probability of success, drug sales, and royalty rates, investors may expect a return of 28%, but with a 22% probability of total loss. Such return distributions may be attractive to hedge funds, family offices, and philanthropic investors seeking both social impact and financial return. Return distributions palatable to mainstream investors may be achieved by funding multiple platform trials simultaneously and securitizing the aggregate cash flows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- MIT Laboratory for Financial Engineering, Cambridge, Massachusetts, United States of America.
- Questrom School of Business, Boston University, Boston, Massachusetts, United States of America.
- QLS Advisors, Cambridge, Massachusetts, United States of America.
- Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Boston, Massachusetts, United States of America.
- MIT Sloan School of Management, Cambridge, Massachusetts, United States of America.
- MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, Massachusetts, United States of America.
ORCID-Profile: Joonhyuk Cho, Eugene Sorets, Andrew W Lo
Zitieren
APA
Cho, J., Sorets, E., Chaudhuri, S., De Mattos, A., Drake, K., Cudkowicz, M. E., Ortiz, R., Hasenoehrl, M., Chase, M., Harkey, B., Paganoni, S., Frishkopf, J., & Lo, A. W. (2025). Financing drug development via adaptive platform trials. PLOS One, 20(7), e0325826. https://doi.org/10.1371/journal.pone.0325826
Vancouver
Cho J, Sorets E, Chaudhuri S, De Mattos A, Drake K, Cudkowicz ME, et al. Financing drug development via adaptive platform trials. PLOS One. 2025;20(7):e0325826. doi:10.1371/journal.pone.0325826
BibTeX
@article{Cho2025,
author = {Cho, Joonhyuk and Sorets, Eugene and Chaudhuri, Shomesh and De Mattos, Annette and Drake, Kristin and Cudkowicz, Merit E and Ortiz, Ricardo and Hasenoehrl, Meredith and Chase, Marianne and Harkey, Brittney and Paganoni, Sabrina and Frishkopf, John and Lo, Andrew W},
title = {Financing drug development via adaptive platform trials},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {7},
pages = {e0325826},
doi = {10.1371/journal.pone.0325826}
}
EUVIMED